Risk factors for carbapenem-resistant acinetobacter baumannii infections at a tertiary care hospital in New Caledonia, South Pacific

Scandinavian Journal of Infectious Diseases

Volumn 42, Issue 11-12, 2010, Pages 821-826

  Le Hello, Simon ^a   Falcot, Virginie ^a   Lacassin, Flore ^b   Mikulski, Marc ^b   Baumann, Francine ^a  

^a Institut Pasteur de Nouvelle Caledonie Noumea   (New Caledonia)

^b Centre Hospitalier Territorial   (New Caledonia)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; CLAVULANIC ACID; COLISTIN; CORTICOSTEROID; IMIPENEM; IMMUNOSUPPRESSIVE AGENT; LEVOFLOXACIN; MEROPENEM; OFLOXACIN; OXACILLIN; PIPERACILLIN PLUS TAZOBACTAM; PRISTINAMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULTAMICILLIN; TICARCILLIN; TIGECYCLINE; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; BACTERIUM ISOLATE; CARBAPENEM RESISTANT ACINETOBACTER BAUMANNII INFECTION; CONTROLLED STUDY; EPSILOMETER TEST; FEMALE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANCE BACTERIAL INFECTION; NEW CALEDONIA; RISK FACTOR; TERTIARY HEALTH CARE; TREATMENT OUTCOME; WARD;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADULT; AGED; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; CARBAPENEMS; CROSS INFECTION; FEMALE; HOSPITALS; HUMANS; MALE; MIDDLE AGED; NEW CALEDONIA; RISK FACTORS; TREATMENT OUTCOME;

EID: 78549292820     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2010.496087     Document Type: Article

References (24)

1. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008;21:538-82.
2. Heritier C, Poirel L, Lambert T, Nordmann P. Contribution of acquired carbapenem-hydrolysing oxacillinases to carbapenem resistance in Acinetobacter baumannii. Antimicrob Agents Chemother 2005;49:3198-202.
3. Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo- â -lactamases: the quiet before the storm? Clin Microbiol Rev 2005;18:306-25.
4. Park YK, Peck KR, Cheong HS, Chung DR, Song JH, Ko KS. Extreme drug resistance in Acinetobacter baumannii infections in intensive care units, South Korea. Emerg Infect Dis 2009;8:1325-7.
5. Le Hello S, Falcot V, Lacassin F, Baumann F, Nordmann P, Naas T. Molecular epidemiology of carbapenem-resistant Acinetobacter baumannii in New Caledonia. Clin Microbiol Infect 2008;14:977-81.
6. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC defi nitions for nosocomial infections. Am J Infect Control 1988;16:128-40.
7. Esen S, Leblebicioglu H. Prevalence of nosocomial infections at intensive care units in Turkey: a multicentre 1-day point prevalence study. Scand J Infect Dis 2004;36:144-8.
8. Hé ritier C, Poirel L, Fournier PE, Claverie JM, Raoult D, Nordmann P. Characterization of the naturally occurring oxacillinase of Acinetobacter baumannii. Antimicrob Agents Chemother 2005;49:4174-9.
9. Clinical and Laboratory Standards Institute (CLSI). Standard M100-S16. Performance standards for antimicrobial susceptibility testing. 16 th Informational supplement. Wayne, PA: CLSI; 2006.
10. Van Looveren M, Goossens H; ARPAC steering group. Antimicrobial resistance of Acinetobacter spp. in Europe. Clin Microbiol Infect 2004;10:684-704.
11. Dalla-Costa LM, Coelho JM, Souza HA, Castro ME, Stier CJ, Bragagnolo, et al. Outbreak of carbapenem-resistant Acinetobacter baumannii producing the OXA-23 enzyme in Curitiba, Brazil. J Clin Microbiol 2003;41:3403-6.
12. Coelho JM, Turton JF, Kaufmann ME, Glover J, Woodford N, Warner M, et al. Occurrence of carbapenem-resistant Acinetobacter baumannii clones at multiple hospitals in London and Southeast England. J Clin Microbiol 2006;44: 3623-7.
13. Jeon BC, Jeong SH, Bae IK, Kwon SB, Lee K, Young D, et al. Investigation of a nosocomial outbreak of imipenemresistant Acinetobacter baumannii producing the OXA-23 beta-lactamase in Korea. J Clin Microbiol 2005;43:2241-5. (Pubitemid 40656234)
14. Srinivasan VB, Rajamohan G, Pancholi P, Stevensen K, Tadesse D, Patchanee P, et al. Genetic relatedness and mole cular characterization of multidrug resistant Acinetobacter baumannii isolated in central Ohio, USA. Ann Clin Microbiol Antimicrob 2009;8:21.
15. Niumsup PR, Boonkerd N, Tansawai U, Tiloklurs M. Carbapenem-resistant Acinetobacter baumannii producing OXA-23 in Thailand. Jpn J Infect Dis 2009;62:152-4.
16. Mansour W, Poirel L, Bettaieb D, Bouallegue O, Boujaafar N, Nordmann P. Dissemination of OXA-23-producing and carbapenem- resistant Acinetobacter baumannii in a University Hospital in Tunisia. Microb Drug Resist 2008;14:289-92.
17. Naas T, Levy M, Hirschauer C, Marchandin H, Nordmann P. Outbreak of carbapenem-resistant Acinetobacter baumannii producing the carbapenemase OXA-23 in tertiary care hospital of Papeete, French Polynesia. J Clin Microbiol 2005;43:4826-9.
18. Ye JJ, Huang CT, Shie SS, Huang PY, Su LH, Chiu CH, et al. Multidrug resistant Acinetobacter baumannii: risk factors for appearance of imipenem resistant strains on patients formerly with susceptible strains. PLoS One 2010;5:e9947.
19. Lee SO, Kim NJ, Choi SH, Kim TH, Chung JW, Woo JH, et al. Risk factors for acquisition of imipenem-resistant Acinetobacter baumannii: a case - control study. Antimicrob Agents Chemother 2004;48:224-8.
20. Falagas ME, Bliziotis IA, Siempos II. Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case - control studies. Crit Care 2006;10:R48.
21. Robenshtok E, Paul M, Leibovici L, Fraser A, Pitlik S, Ostfeld I, et al. The signifi cance of Acinetobacter baumannii bacteraemia compared with Klebsiella pneumoniae bacteraemia: risk factors and outcomes. J Hosp Infect 2006;64: 282-7.
22. Wareham DW, Bean DC, Khanna P, Hennessy EM, Krahe D, Ely A, et al. Bloodstream infection due to Acinetobacter spp: epidemiology, risk factors and impact of multi-drug resistance. Eur J Clin Microbiol Infect Dis 2008;27: 607-12.
23. Falagas ME, Karveli EA, Kelesidis I, Kelesidis T. Community- acquired Acinetobacter infections. Eur J Clin Microbiol Infect Dis 2007;26:857-68.
24. Kopterides P, Koletsi PK, Michapoulos A, Falagas ME. Exposure to quinolones is associated with carbapenem resistance among colistin-susceptible Acinetobacter baumannii blood isolates. Int J Antimicrob Agents 2007; 30:409-14.